COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital

Mucormycosis Clinical Trial

Official title:

COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05074043
• Other study ID #: COVID-19 with mucormycosis
• Status: Completed
• Start date: March 1, 2021
• Est. completion date: July 30, 2021

Study information

• Verified date: October 2021
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

We aimed to describe the frequency; presentations, predictors, in-hospital outcome of mucormycosis patients in the scope of COVID-19.

All patients with COVID-19 associated Mucormycosis (CAM) admitted to Assuit University Hospital between March 1, 2021, and July 30, 2021, were included in this study. The patient characteristics, the site of mucormycosis, the comorbidities, the steroids usage, and the outcome were analyzed in people with COVID-19.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 433
• Est. completion date: July 30, 2021
• Est. primary completion date: June 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:We recruited all cases admitted to Assuit University Hospital for the management of COVID-19 and/or associated complications between March 1, 2021, and July 30, 2021, specifically those with probable mucormycosis based on clinical condition. At various times, internists, intensivists, neurologists, and otolaryngologists were among the specialists who assessed and treated them. Clinical; radiological and histopathological confirmed cases of mucormycosis with coexisting or previous history of COVID-19 were included in this study.

-

Exclusion Criteria:Participants with fungal infections other than mucormycosis or without a confirmed diagnosis of COVID-19 (or serological evidence of preceding COVID-19) were excluded.

-

Related Conditions & MeSH terms

• Mucormycosis
• Zygomycosis

Intervention

Combination Product:
• antiviral, surgical
surgical debridment

Locations

Country	Name	City	State
Egypt	Marwa Abdelrady	Asyut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	incidence of covid19 associated mucor		3 months